Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Association Between Hormonal Maintenance Therapy and Progression-Free Survival in Advanced Epithelial Ovarian Cancer Patients: A Retrospective Study Publisher



Sadeghi A1 ; Torki M1 ; Ashrafi F1 ; Akbari M2 ; Pourajam S1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Esfahan, Iran
  2. 2. Department of Epidemiology and Statistics, Isfahan University of Medical Science, Esfahan, Iran

Source: Indian Journal of Gynecologic Oncology Published:2024


Abstract

Introduction: This retrospective study aimed to investigate the association between hormonal maintenance therapy and progression-free survival (PFS) in advanced (stage 3 or 4) epithelial ovarian cancer patients who achieved complete clinical remission with first-line chemotherapy. Methods: The study included 64 advanced HGSOC patients who received Tamoxifen, Letrozole or sequential Tamoxifen followed by Letrozole as maintenance therapy versus no maintenance treatment. The primary outcome measure was progression-free survival (PFS) at 12 and 24 months. The association between patients’ characteristics and PFS was also analyzed. Results: Tamoxifen and Letrozole were the most commonly used maintenance treatments. The mean PFS was 20.56 ± 11.48 months. The study found that Letrozole played a significant role in prolonging PFS compared to Tamoxifen, sequential Tamoxifen followed by Letrozole or no maintenance group. The frequency of PFS at 12 and 24 months was also reported, with Letrozole showing a better effect in the long term “P = 0.006”. The majority of patients did not have significant toxicities whilst on Letrozole or Tamoxifen. Conclusion: Hormonal therapy can be an effective maintenance treatment option for advanced ovarian cancer, and Letrozole may be a preferred option for prolonging PFS in advanced HGSOC patients. © The Author(s) under exclusive licence to Association of Gynecologic Oncologists of India 2024.
Related Docs
1. Prognostic Value of Peritoneal Washing Cytology in Gynecologic Malignancies: A Controversial Issue, Asian Pacific Journal of Cancer Prevention (2014)
2. A Rare Case of Uterine Leiomyosarcoma Following the Use of Tamoxifen in a Patient With Breast Cancer, Journal of Isfahan Medical School (2021)
3. In Vitro Evaluation of the Pogostone Effects on the Expression of Pten and Dact1 Tumor Suppressor Genes, Cell Cycle, and Apoptosis in Ovarian Cancer Cell Line, Research in Pharmaceutical Sciences (2022)
4. The Association Between Oral Contraceptive Pills and Ovarian Cancer Risk: A Systematic Review and Meta-Analysis; [Association Entre Pilules Contraceptives Orales Et Risque De Cancer De L'ovaire: Une Revue Systematique Et Une Meta-Analyse], Bulletin du Cancer (2024)
5. Comparison of Acute Side Effects Prevalence of Femara and Letrofem in Postmenopausal Women With Breast Cancer, Journal of Isfahan Medical School (2010)
6. Evaluation of the Relationship Between Cd163 Positive Macrophages and Prognostic Factors in Serous Ovarian Tumors, Immunopathologia Persa (2020)
7. The Association Between Oral Contraceptive Pills and Subtypes of Ovarian Cancer: A Systematic Review and Meta-Analysis, Journal of Biostatistics and Epidemiology (2024)
8. Efficacy and Safety of Flot Regimen Vs Dcf, Folfox, and Ecf Regimens As Perioperative Chemotherapy Treatments for Resectable Gastric Cancer Patients; a Report From the Middle East, Research in Pharmaceutical Sciences (2022)
Experts (# of related papers)
View all Related Experts
Ali Akhavan (1)
Mehran Sharifi (1)